Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD.
Carmen AdduciLorenzo SempriniFrancesca PalanoMaria Beatrice MusumeciMassimo VolpeCamillo AutorePietro FranciaPublished in: Pacing and clinical electrophysiology : PACE (2019)
ATP is moderately effective for the treatment of monomorphic VTs in HCM patients. However, the rate of appropriate ATP therapies is low, ATP is often prematurely delivered, and ATP-induced arrhythmia degeneration is of concern.
Keyphrases
- hypertrophic cardiomyopathy
- left ventricular
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- catheter ablation
- heart failure
- high glucose
- diabetic rats
- atrial fibrillation
- patient reported outcomes
- endothelial cells
- drug induced
- replacement therapy
- patient reported